Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability of numerous glucose-lowering therapies and clear guidelines for T2D management. Tackling clinical or therapeutic inertia, where the person with diabetes and/or their healthcare providers do not intensify treatment regimens despite this being appropriate, is key to improving patients' long-term outcomes. This gap between best practice and current level of care is most pronounced when considering insulin regimens, with studies showing that insulin initiation/intensification is frequently and inappropriately delayed for several years. Patient-and physicianrelated factors both contribute to this resistance at the stages of insulin initiation, titration and intensification, impeding achievement of optimal glycaemic control. The present review evaluates the evidence and reasons for this delay, together with available methods for facilitation of insulin initiation or intensification.
| INTRODUCTION
The benefits of timely glycaemic control for reducing the risk of micro-and macrovascular complications are well established, [1] [2] [3] [4] yet many people with type 2 diabetes (T2D) remain in poor glycaemic control. 5 Diabetes care has improved in the USA, 6 Europe 7-9 and elsewhere 10 in recent decades, as reflected in the increased proportion of people with diabetes meeting national glycaemic targets; however, there remains a substantial number of people with T2D who have inadequate glycaemic control. In the UK, for example, a third of people with T2D do not achieve glycated haemoglobin (HbA1c) levels ≤7.5% (59 mmol/mol). 11 This is despite the latest guidelines recommending intensification of current diabetes treatment if a person's individual HbA1c target is not achieved within 3 months, 12 or within 3 to 6 months, after initiation. 13 Delayed treatment intensification in uncontrolled patients can increase the risk of diabetes-related complications in later life. For example, the 10-year follow-up of the UK Prospective Diabetes Study showed that intensive glucose control (sulphonylurea or insulin or, if obese, metformin) from diagnosis was associated with significantly decreased risks of myocardial infarction, death from any cause and microvascular disease. 3 In addition, a retrospective cohort study revealed that a 1-year delay in treatment intensification in patients with poor glycaemic control significantly increased the risk of myocardial infarction (67%, hazard ratio confi- Recent studies show that people often remain above target for several years before treatment intensification. 5 This is true of every step in the treatment pathway, but clinical or therapeutic inertia appears to be more pronounced when considering addition of insulin, particularly in insulin-naïve people. 5 Reasons for this can be related to the healthcare professional (HCP) and/or the person with diabetes, and differ depending on which stage of their treatment strategy a person is at. Poor glycaemic control can be partly attributed to delayed initiation of insulin (initiation inertia), lack of dose adjustment (titration inertia) and delayed intensification (intensification inertia), all of which constitute therapeutic inertia. 15 The evidence and reasons for inertia at these three steps are discussed in further detail below, together with the methods used to tackle barriers to insulin optimization ( Figure 1 and Table 1 ). 45 In a UK cohort study in insulin-naïve people with T2D receiving oral antidiabetic drugs (OADs) who did not meet glycaemic targets, only 25% initiated basal insulin within~2 years and 50% withiñ 5 years. 46 Another UK study in 14 824 people with T2D (on ≥2
OADs) found that the median time from initiating the final OAD to beginning insulin treatment was 7.7 years, despite a mean HbA1c >8% (64 mmol/mol). 47 Notably, only 847 (26.9%) of the 3153 participants with poor glycaemic control following initiation of their last oral agent were prescribed insulin during the study. More recently, a retrospective cohort study in >80 000 people in the UK revealed that the median time for an OAD-treated participant between becoming above target until insulin initiation ranged from 6.0 to 7.1 years. 44 The evidence therefore suggests that insulin initiation is inappropriately delayed for several years. The majority of studies on clinical or therapeutic inertia in T2D have been conducted in the USA, the UK and Canada; however, there are a small number of multinational studies, such as the Study of Once Daily Levemir (SOLVE) 48 and Time2DoMore. 49 Findings from the SOLVE study, involving 17 374 people globally, confirmed that initiation inertia is a global problem, the extent of which varies between countries. For example, the UK cohort of SOLVE had a higher baseline HbA1c at time of insulin initiation, compared with the global population of SOLVE (9.8% vs 8.9%, respectively), despite having a shorter duration of disease. 48, 50 In addition, the proportion of people with HbA1c >9% at time of insulin initiation varied from 23% (Poland) to 64% (UK and Turkey), suggesting the level of inertia varies between countries. 48 
| Reasons for initiation inertia
The reasons that people with diabetes and HCPs often resist or postpone insulin initiation are complex and frequently overlap. For example, both groups often have concerns regarding hypoglycaemia, weight gain and adherence. 51, 52 A global survey of 1250 HCPs found that 75.5% would treat more aggressively were it not for the risk of hypoglycaemia with insulin, 53 while "problematic hypoglycaemia" was one of the most frequent patient-reported reasons for avoiding insulin therapy in a survey of 708 insulin-naïve people with T2D. 54 Similarly, HCPs and people with diabetes worry that insulin regimens will be too burdensome to adhere to, 54 with 54.5% of HCPs (n = 1250) and 27.6% of people with diabetes (n = 1530) citing "taking insulin at prescribed time or with meals every day" as difficult. 53 Weight gain is another shared concern, and one that does not diminish as patients become more insulin-experienced. 55 When considering insulin therapy, these issues can manifest as a negative conversation in which HCPs delay insulin initiation while their patient has one last attempt to improve their lifestyle. 54 Consequently, people with diabetes may perceive insulin therapy as an indication of failure, or as a punishment for their unhealthy behaviours, rather than a solution to obtaining glycaemic control.
The most problematic of patient-related barriers to insulin initiation are largely covered above, but other barriers may be psychological, including fear of injections and/or fear of self-measuring blood glucose, 56, 57 and the misconception that quality of life will worsen considerably. 55 Concerns may vary from person to person, and may be more severe in a person with depression. For example, a person with diabetes is almost twice as likely to be diagnosed with depression as someone without diabetes and, unsurprisingly, these insulinrelated issues are more overwhelming to a patient with comorbid depression. 58 Comorbid depression is a predictor of poor health outcomes in diabetes, 59 yet depression only was not associated with postponement of insulin initiation in two longitudinal studies. 59, 60 Nevertheless, individuals with both elevated levels of depression and anxiety were less likely to start insulin therapy. 60 The patients in this particular group might have experienced insulin-related anxieties, which could explain the apparent disparity between these findings, but replication studies in this area are needed to test this hypothesis.
In other cases, HCPs can overestimate patient concerns, particularly fear of injection, and further contribute to this barrier. 61 In terms of barriers solely relevant to the HCP, a lack of experience in initiating insulin -and of the time to do so -often impact treatment decisions, While hypoglycaemia and weight gain remain important side effects of insulin therapy, the therapeutic landscape of diabetes is continually evolving and many improvements to the absorption kinetics 66 and delivery 67, 68 of insulin therapy have been observed in recent years, and will be advanced in ongoing and future studies. A detailed look at the fundamental unmet needs with insulin therapy and the advances required to progress towards an ideal agent for diabetes management are beyond the scope of the present review, but the availability and application of recent developments is discussed further in the following sections.
| Methods to tackle initiation inertia
As chronic disease management is now mainly the responsibility of primary care, research has focused on how to best equip and educate primary care physicians. One of the most successful methods so far has been to restructure primary care such that insulin initiation is assisted, or led, by a nurse practitioner. 69 For example, a recent cluster randomized controlled trial in Australia showed that a "Stepping ) and no deterioration in emotional wellbeing. 21 Results from other studies suggest similar success would be observed in Europe 70 and the USA. 37 One reason why nurse-led insulin initiation results in better outcomes compared with usual care might be that nurses are better placed to help administer and titrate insulin and to address any concerns as part of their ongoing contact with patients for similar tasks/procedures, thereby strengthening that relationship. In contrast, GPs might not see patients as often and, when they do, the patient might have several problems they wish to discuss in a single appointment, while GPs 83 In terms of insulin omission, findings from a systematic review indicated that the insulin adherence rate (the proportion of doses taken as prescribed) among people with T2D was 62% to 64%. 84 In people with T2D initiating insulin therapy, another report found that 4.5% of people had unfilled prescriptions and a further 26% never obtained a refill. 85 
| Reasons for titration inertia
Many of the barriers that delay intensification with insulin continue to pose a problem following initiation. For instance, there is often a lack of HCP resources, assistance and education for patients regarding effective titration. 5 Ongoing patient fear of hypoglycaemia and weight gain can result in under-titration, 86 and concerns about impact on daily life can result in insulin omission and infrequent self- 
| Methods to tackle titration inertia
Alternative titration algorithms can simplify regimen complexity, and thereby help patients to manage their diabetes more conveniently and effectively. For example, patient-led titration using simple titration algorithms has resulted in greater HbA1c reductions vs physician-led adjustment of either OADs (−1.55% vs −1.25%, −17 vs −14 mmol/mol, P = .005; the INSIGHT study) 32 or insulin glargine (−1.22% vs −1.08%, −13 vs −12 mmol/mol, P < .001; AT.LANTUS). 33 In addition to simpler titration algorithms, educational selfmanagement programmes for people with diabetes are key to optimizing clinical outcomes for insulin-naïve and insulin-experienced patients alike. Indeed, diabetes self-management education (DSME) is an integral aspect of the latest guidelines for management of T2D. 12, 88 A recent meta-analysis showed that mean change in HbA1c was −0.74% (−8 mmol/mol) and −0.17% (−2 mmol/mol) for intervention with DSME and control, respectively. Greater HbA1c reductions were reported with DSME when contact with the patient numbered ≥10 hours and/or combined group and individual sessions. 89 This suggests that DSME helps patients to manage their diabetes treatment and adopt positive behavioural changes. Other studies support this, 90 with one randomized pragmatic trial showing that structured education (Diabetes Conversation Map™) resulted in a greater proportion of patients achieving their American Association of Diabetes
Educators Self-Care Behaviours™ framework (AADE7) behavioural goals at 3 months than was seen with usual care. 91 Adherence, particularly in terms of aggressiveness or intensity of titration, is difficult to quantify, but these studies do show that DSME is effective at tackling one facet of titration inertia. Longer-term studies are required to establish whether these changes in patient behaviours are maintained, as there have been mixed results so far. 27, [92] [93] [94] There are several new tools to help people manage their diabetes effectively, which have an in-built dose adjustment algorithm for patients with T2D receiving basal insulin. 95, 96 Full results are yet to be pub- clinical decision-making function, suggesting that this module requires improvement, with input from both the physician and user. 97 Similarly, studies on app-based interventions for elderly people with diabetes have yielded promising but varying results, depending on the particular app used. 98 Further adjustments and evaluation are required to help realize the full potential of these novel tools, particularly with respect to insulin management, which was not the primary focus of many of these DMSE and app-based interventions.
| THERAPY INTENSIFICATION INERTIA

| Evidence of intensification inertia
As T2D progresses, intensification of basal insulin therapy may be required. This might be addition of a bolus insulin dose in response to prandial blood glucose excursions, or intensification with a noninsulin agent in response to problems with weight gain, hypoglycaemia or in order to tackle additional underlying pathophysiological defects of T2D. 12 There are relatively few studies that investigate inertia with insulin intensification, but similar delays have been were intensified with bolus insulin; 43% were intensified with premix insulin and 7.4% were intensified with glucagon-like peptide-1 receptor agonists (GLP-1RAs). 99 
| Reasons for intensification inertia
The reasons for delayed intensification can vary depending on which strategy is being considered. When discussing addition of prandial Continued uptitration of basal insulin may also be favoured over an additional agent because the HCP does not have adequate time available to initiate or does not believe the patient will manage a more complex regimen. To take full advantage of the advances in diabetes therapy, many of the methods discussed with regard to initiation inertia -such as education of, and effective communication between, HCPs and patients -would also warrant employment at this stage.
| SYSTEM-LEVEL BARRIERS TO APPROPRIATE INSULIN INITIATION AND INTENSIFICATION
System-level barriers affect all stages of insulin management, and indeed healthcare in general. These barriers have been discussed briefly in earlier sections and are summarized here. As mentioned earlier, the development of new therapies and devices to meet the unmet needs of diabetes management is key to tackling barriers to initiation and intensification inertia. However, the relative expense of these developments, a system-level barrier, will also be paramount in 
| CONCLUSION
Therapeutic inertia in T2D is a global issue that impedes achievement of glycaemic control, particularly in patients requiring insulin therapy.
Reasons for this span the patient, physician and system levels and include misconceptions surrounding insulin therapy, lack of experience in primary care with managing insulin regimens, affordability, and lack of time, resources and/or motivation to optimize insulin use. 
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